Corporate Presentation

On December 2, 2019 NantKwest presented the corporate presentation (Presentation, NantKwest, DEC 2, 2019, https://nantkwest.com/wp-content/uploads/2019/12/NantKwest%20KOL%20December%202019%20Presentation.pdf [SID1234551874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


EOC Pharma Raises $71 Million in C Round for China Development of In-Licensed Oncology Drugs

On December 2, 2019 EOC Pharma, the oncology development arm of China in-licensing company Eddingpharm, reported that it raised $71 million in a Series C round led by Tigermed, TF Capital and Yingke PE (Press release, ChinaBio, DEC 2, 2019, View Source [SID1234551857]). Headquartered in Taizhou, EOC manufactures and commercializes oncology products for China use that require mid to late stage clinical development for registration . It currently has a pipeline of six novel products from global biopharmas, including its most recent in-licensing, a Shionogi HER2/EGFR inhibitor intended to treat brain metastasis in advanced metastatic breast cancer patients. Two years ago, EOC completed a $32 million B financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference

On December 2, 2019 Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, reported that its Chief Executive Officer Doug Manion, MD, will present at the Piper Jaffray 31st Annual Healthcare Conference, to be held December 3-5 at the Lotte New York Palace in New York (Press release, Kleo Pharmaceuticals, DEC 2, 2019, View Source [SID1234551849]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During his presentation, Dr. Manion will provide an overview of Kleo’s development strategy for its pipeline of small molecule and synthetic peptide compounds that function similar to highly complex biologics, while offering multiple potential advantages. The overview will also outline Kleo’s key value drivers including its proprietary technology platforms that drive in-house drug development and partnership opportunities, the multiple in-house and collaborative channels through which it is building its immuno-oncology pipeline and its discovery collaboration with PeptiDream. Human studies are anticipated in 2020 for Kleo’s first product candidate to move into the clinic, CD38-ARM, a CD38 targeting antibody recruiting molecule (ARM) to treat multiple myeloma.

Dr. Manion will also discuss another platform technology at Kleo, which uses site-directed, chemical conjugation of off-the-shelf antibodies to enhance or add functionality. Monoclonal antibody therapy enhancers (MATEs) offer a number of opportunities to optimize or repurpose biologics currently in development.

Details of the presentations are as follows:

Event:

31st Annual Piper Jaffray Conference

Date:

December 3

Time:

2:10-2:30 p.m. EST

Location:

Lotte New York Palace, New York

Room:

Harlem Track – Kennedy 2, 4th Floor

CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference

On December 2, 2019 CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reported that the Company will present an overview of the company at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5, 2019 in New York, NY, and meet with investors in 1×1 meetings throughout the day (Press release, Cytosorbents, DEC 2, 2019, View Source [SID1234551848]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Jaffray 31st Annual Healthcare Conference
Where: Lotte New York Palace, 455 Madison Ave, New York, NY
When: Thursday, December 5, 2019 from 11:50AM-12:10PM EST
Webcast: Piper Jaffray 31st Annual Healthcare Conference Webcast Link

A live webcast of the presentation will be available at the above webcast link. An archived replay of the webcast will be available for 90 days following the event.

ORIC Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

On December 2, 2019 ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that Matthew Panuwat, Chief Business Officer of ORIC, will present at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 10:50 a.m. ET in New York City (Press release, ORIC Pharmaceuticals, DEC 2, 2019, View Source [SID1234551847]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!